Agamree2025年最新价格

Agamree is an oral suspension developed by Swiss pharmaceutical company Santhera Pharmaceuticals. It is mainly used to treat Duchenne muscular dystrophy (DMD) in patients 2 years old and above. Its active ingredient is Vamorolone.

The latest price of Agamree in 2025

With the advancement of global medical technology, Agamree, as an important drug in the treatment of DMD, has attracted much attention in terms of price and accessibility. The following will introduce the latest price information and market dynamics of this drug.

Launching and medical insurance status

Agamree is currently on the market in countries such as Germany, the United States, and the United Kingdom, but it has not yet entered the Chinese market and has not been included in Chinese medical insurance. The original drug is produced by Santhera Pharmaceuticals and will be launched in Germany on January 15, 2024.

Chinese patients who want to purchase Agamree must obtain it through legal channels such as overseas medical institutions or online platforms. There are no generic drugs of Agamree on the market.

The latest price

The price of Agamree produced in Switzerland is about US$9,764 per box (100mL). This price may fluctuate due to exchange rates, transportation costs and purchasing channels, and is for reference only.

The ways to obtain Agamree are relatively limited. Patients can consult professional medical institutions to learn about the overseas drug purchase process. They need to pay attention to Agamree’s transportation time and storage requirements to avoid affecting the efficacy of the drug.

Agamree usage and dosage

Using Agamree correctly can reduce the chance of side effects. The following content details its usage and dosage adjustment principles.

Routine dosage and medication requirements

The recommended dosage of Agamree is 6 mg/kg once a day. Taking it with meals can improve the absorption rate. For patients weighing more than 50 kg, the daily dose should not exceed 300 mg. Some patients may respond to a lower dose (2 mg/kg/day), which needs to be adjusted based on individual response.

Dose adjustment for special groups

Patients with mild to moderate hepatic impairment need to reduce the dose to 2 mg/kg/day, and the upper limit is 100 mg for those weighing over 50 kg. When coadministered with strong CYP3A4 inhibitors, the dose of Agamree is adjusted to 4 mg/kg/day, with an upper limit of 200 mg. After long-term use, the dose must be gradually reduced to avoid the risk of adrenal insufficiency.

Shake the suspension for 30 seconds before taking the medicine. Unused medicines within 3 months after opening the bottle should be discarded to prevent the deterioration of Agamree ingredients and affecting the patient's health.

How to store Agamree

Proper storage of Agamree can prevent the medicine from deteriorating. The following are the specific storage conditions and precautions.

Unopened and opened storage requirements

Unopened Agamree needs to be stored upright at room temperature between 20°C and 25°C, and short-term fluctuations to 15°C-30°C are allowed. After opening, the vial should be placed in a refrigerator at 2°C-8°C to avoid freezing. Return to the refrigerator immediately after each use.

Validity period and disposal

The validity period of unopened medicines is based on the packaging label. It must be used up within 3 months after opening, and the remaining liquid medicine should be discarded. If the storage temperature is abnormal or the medicinal solution appears stratified or discolored, use should be stopped immediately.

Agamree may cause side effects such as Cushingoid changes, mood swings, and gastrointestinal reactions. If severe discomfort or infection symptoms occur, you should contact your doctor promptly to adjust the treatment plan.